Eldelumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Eldelumab
Accession Number
DB06116
Type
Biotech
Groups
Investigational
Description

MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

Synonyms
Not Available
External IDs
BMS-936557 / MDX-1100
Categories
UNII
15O91A27I5
CAS number
946414-98-8

Pharmacology

Indication

Investigated for use/treatment in ulcerative colitis.

Pharmacodynamics
Not Available
Mechanism of action

MDX-1100 binds selectively to CXCL10 and blocks CXCL10 induced calcium flux and cell migration.

TargetActionsOrganism
UC-X-C motif chemokine 10Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Eldelumab.
AbituzumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Eldelumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Eldelumab.
AducanumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Eldelumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eldelumab.
AlirocumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Eldelumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentUlcerative Colitis1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentUlcerative Colitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
Chemotactic for monocytes and T-lymphocytes. Binds to CXCR3.
Gene Name
CXCL10
Uniprot ID
P02778
Uniprot Name
C-X-C motif chemokine 10
Molecular Weight
10880.915 Da

Drug created on November 18, 2007 11:30 / Updated on December 02, 2019 07:18